Securities code: 002432 securities abbreviation: Andon Health Co.Ltd(002432) Andon Health Co.Ltd(002432) investor relations activity record form investor relations activity category √ specific object research □ analyst meeting □ media interview □ performance briefing □ press conference □ roadshow activity □ on-site visit □ name of other online participants and name of personnel unit name of Anxin securities Xu Yanpeng Anxin asset management Liu yaya Caitong Securities Co.Ltd(601108) Zhu Haidong ChuangJin Hexin Mao Dingding Dacheng Fund Chen Quan Long Yang Hong Yu Zou Jiandong finance fund sun Chenyang Dongfang alpha Chengke Donghai securities self operated Shi Yang Dongwu asset management Lu Yitao Fengjing capital Wang Shichao Fu Anda Liu Yunpeng Xu Rui Fuguo fund Li Miao Lin Qing Peng Weixi Gangli Investment Ma pengge Ru investment lanshui ICBC Credit Suisse Li Ganning Ding Yang Zhu Teng Guhe assets Wang Shengrui Everbright Baode Trust fund Zhang Xiangyu Guangzheng asset management Wang Hongyu Gf Securities Co.Ltd(000776) Wu jiashuan Guangfa fund Wang Yan Guangfa Asset Management Yang Jieqi Guohai Franklin fund Liu muguo fund Huang Shuang Luo Yanting Guojun asset management Li Zibo Guolian Securities Co.Ltd(601456) Zhao Ziqi Guotai Junan Securities Co.Ltd(601211) Any forest Lu Jia sampan Guotai Ruifeng Wang Tianci Haifeng Tong fund Liu Yang Haitong self run Hu Xing and Mei capital Wang Rong harmony and harmony Chen Kai Hongta adorable red soil innovation fund Liao Xingxing Hong Cheng investment Yin Meng Fan Xiangyu Huaan Securities Co.Ltd(600909) Tan Guochao Huabao securities Qi Zhen Wei Yangfan Valin Jinshan Zhang Qingzhu Chinese business fund Ma Bu Yun Huatai Bai Rui Xie Feng Huaxia Securities Wang Zeshi sun Mingda Huaxia jiuying Wang Lei Huayin fund Zhang Yuning HSBC Jinxin Luo Ying huitianfu fund Xie Jie Huili Huili fund Li Boyi Yu Chenjun Huichen asset management Zhou Lingming assets Wang Jingcheng Harvest Fund Hao Miao Xia Guoqiang CCB fund Ma MuQing bocom Schroeder Fund Zhu Yining Jinxin fund Huang Biao Tan Zhimi Jinyou Chuangzhi Ruan SHUAIJIN investment Ben Guo Yuanqing Jingshun Great Wall Fund Jiang Xueting Chen Jinglin Junmao investment Chen Xiaoshen Liyan investment Wang Haoyu Minsheng Jiayin Wang Yongxin Chen Jiexin Agricultural Bank Huili Lei noan fund Ding Yunbo Ouyang Juan Nord fund Zhu Mingrui Panjing assets Cao Shanshan Pengyang fund Yan Ding’an ping an asset management Xu Wangyang LV Zenan Puyin Anson Zhao ningqin Wen Qianhai Baichuan Dong Haotian endowment insurance Wang Xiaoqi financing fund Yu Sihui Ruihua capital Zhang Xiaobing Ruiyang investment Zhang Zhuying Runda Sheng An Hu Jiandong Shanghai Investment Morgan Wang Lijun Shanghai Banking fund Yang Jiannan Ji Xiaotian Shenyin Wanguo quarter new star Shen Wanling Xin Wang Qilin Shenwu assets Liu Yu Liang Shennong investment Zhang Weishen assets Wang Yumei initial securities Zhou Xianpei private capital Wu Yaping The Pacific Securities Co.Ltd(601099) securities Sheng Lihua TEDA Manulife Zhang Shuai Taikang Asset Management Yang Lei Yan Yuan Taikang Hong Kong Ding Shen Liu Qing Tianfeng asset management Wang Yikun Tianhong fund Zhou? Zhang xiulei, Liu Lianmeng, Wang Bin, general investment, Li Yue Wanjia fund, Yang Mengchao, ICIF Qisheng investment, Xing Wudi investment, Peng Xinyue, Xitai investment, Feng shixiangju capital, Deng Qiao, Xinhua pension, Huang Bing, Niu Yue, Xinda, Bank of Australia, Yang Ke, Li Diandian, Xintai life insurance, asset management, Ding Yan Xinghua fund, Huang Bing China Industrial Securities Co.Ltd(601377) Dai Pengju Industrial Global Fund Dai Xinxun yuan capital Qin Ting Yimin fund Zhang Shusheng Galaxy Securities Mao Hongyang Yinhua Fund Luo Zhenhuan Li Xiaohui ginkgo global capital Wang Guanghua Yingfeng capital Zhang Linfei Zhou Dong Yong’an Guofu Li YONGYING fund Zhang Ruiyu Yi assets Xia Fangfang Zhang Yahui Zhu He Chang’an fund Dai chenle China Greatwall Securities Co.Ltd(002939) Chen Weifeng Changsheng fund Zhou Sicong Changxin fund Liang Haoliang took off China Merchants Securities Co.Ltd(600999) Wu Hao Investment Promotion Fund Zhou Yuting China Merchants Securities Co.Ltd(600999) asset management Xu wenzhaowan assets Li Darui Zhengyuan private placement Zhong Xiaolin China Canada Fund Wen Yan CICC fund Zhang Yu China Europe Fund Ren Yizhe Ling Li Zhao Lei China Europe Ruibo investment Lai Hao Zhongrong fund Wu Gang Zhongtai Securities Co.Ltd(600918) Xie MuQing Yu Jiaxi BOC fund Wang Fangzhou Ma Shanyao BOC asset management Jing Yu Shi Li Mingwei Li Wei Chongyang investor Yi Han Guoshou asset Li Yingpeng Youcai investment Zhang Yanan Zhonggeng fund Xiong Zhenghuan Gefei asset Zhang Xin Ping An fund Wu Yuxiao Dongzheng asset management Liu Zhongqun Shanghai Longhang asset Yao Kaifeng YONGTUO investment Wang jiazi’an fund Li mingxuanjia investment Chen ningyiheng investment Tian huangda Changchun Teng assets Liu Tao a Xing invests in Fan Jianping Great Wall Fund Chen Liangdong life assets Zhang Xinya determined capital Liu Ling Hawthorn assets Jiang Lingyun Shibei invests in Chen Wen Zhonggeng fund Zheng Ning ocean capital Wang Yuchen Great Wall Fund Liang Furui haoyuheng invests in Yao Xiaoguang Fusheng Assets Land aviation construction investment management Peng Guoyu Fu Anda fund Li Yutong national highway fund Chen Jianqiang shengmeng assets Teng zheqing Gan Ti Investment Li qiaozhaowan asset Cui leiruiyang investment Peng Yan Zhejiang Yiheng fund Xu Guanhua meiyang investment Hu Zhimin Ganti investment Wang zhouge law asset Hesen CITIC asset management Chen Yuanguang big trust Shi Yu evolutionism asset LAN Zhiyang Fuyun investment Yu Haihai financial holding financial fund Liu Jinyu Huishi asset Zhang Shun zhe Lou Hui Stillbrook fund Chen Zhuhong time January 14, 2022 mode Tencent Name of receptionists of listed companies Chairman: Mr. Liu Yi Secretary of the board of directors: Mr. Wu Tong introduction to the main contents of investor relations activities I. Introduction to the company overview 1. Hello, chairman Liu Yi. I’m glad to communicate with you, Andon Health Co.Ltd(002432) was established in 1995. It is a company making electronic sphygmomanometers. It relies on sphygmomanometers to make its own brand in China ODM production, the company was listed on Shenzhen SME board in 2010. After listing, Andon Health Co.Ltd(002432) connects the electronic sphygmomanometer with the mobile phone. It is the first generation of Internet of things sphygmomanometer, which has been strongly supported by apple. Then we set up a company in Silicon Valley and began to explore the process of hardware, mobile Internet and services. The early mobile Internet and Internet of things brought changes to the company. We expect to seize the opportunity, mainly for internet medical services. In fact, this road is relatively difficult. Internet medicine was not mature outside China at that time, so the early exploration process was also relatively difficult. For about seven years, the company made losses after deducting non recurring profits and losses, but we still decided to explore this road. Finally, we summed up the new model of diabetes care O+O, hoping to extend the medical service from the hospital to the family and from the offline to the online. We began to explore this model in Tianjin metabolic disease hospital and Peking University Hospital in 2016, and expanded this model to the United States in 2019. At present, 47 cities and more than 150 hospitals in China city have managed diabetes according to this mode. The blood sugar control effect of the group of diabetic patients has increased from about 30% to about 60% now. At present, it has cooperated with more than 40 clinics in the United States. Our core is to seize the opportunity of mobile Internet and the Internet of things to change traditional industries. We have made nearly 11 years of efforts. Finally, we identified two core strategies for the company’s development in 2019: first, the promotion of a new O+O model for diabetes care. Second, we carried out in-depth cooperation with Xiaomi in 2014. Xiaomi also invested in ihealth. We learned from Xiaomi’s popular ideas and continued to launch popular products on new retail platforms outside China. The forehead thermometer was released in China together with Xiaomi in 2017. This product is a convenient and reliable forehead thermometer in terms of appearance, performance and other aspects. During the epidemic in 2020, the company contributed to China’s public health and epidemic prevention by providing forehead thermometer products.
After that, the company sold the product in the United States and became a product related to public health and epidemic prevention in the United States. Ihealth also established a brand and opened the market in the United States. With the development of the epidemic in the United States, we also see the opportunity of covid-19 home self-test kit products in the U.S. market, and coordinate the company’s team and resources to carry out relevant work. Jiuan company was not a company with kit as its main product before, but based on the following three reasons, the company decided to apply for FDA EUA authorization with this product. 1. Set up a team in the United States to solve practical problems such as clinical and experimental problems locally; 2. Andon Health Co.Ltd(002432) in other products, have experience in contacting with FDA and are relatively familiar with the relevant requirements of FDA; 3. Facing the U.S. market, ihealth, as an independent brand, has entered the U.S. market. Ihealth obtained 250 million kit orders from HHS in the United States, which is also the largest order in the company’s history. We also hope to make a contribution to epidemic prevention. After all, the virus is our common enemy. We are pleased that the self-test kit can play a role in epidemic screening. Last year, forehead thermometer products participated in public health and epidemic prevention. This year, covid-19 self-test kit also participated in epidemic prevention in the United States. We are also happy to compete with Abbott (Abbott), quidel (Roche), BD and other enterprises. 2、 Q & a session question 1: the company’s products can compete with American companies on the same stage. I’d like to ask the company’s leaders what are the main difficulties in improving the production capacity of antigen kit products, the company’s production capacity planning and later work arrangement a: China has manufacturing capacity and labor resources. In terms of raw material supply, China’s industrial chain exported European kits last year, With the supply capacity of raw materials, the increase of production capacity mainly depends on the supply of labor, but the increase of production capacity takes a time process. The company will comprehensively consider the two factors of efficiency and risk and reasonably plan the production related arrangements. Q2: the company has established a reputation through the sales of kits in the U.S. market. I would like to ask about the company’s follow-up development in the future. For example, after the end of the epidemic, there is not so much demand for antigen kits. Where is the focus of our follow-up development? A: at present, our kit products have orders and contracts in the United States, Ihealth product brand has also improved its popularity in the United States. In the next step, we can further expand sales channels by integrating China’s advantageous technical capabilities and advantageous products. Q3: before we saw our products on the official website, the sales price was $6.99, but now the average price is $9.99. Compared with the competitiveness of our peers, is there a price increase plan? A: the original retail price does not include freight, and the retail price adjustment includes freight, so the actual price has little change, It is mainly used to cover freight. You can see our prices in similar products from Amazon. At present, the company has no price increase plan. Question 4: are raw materials self supplied or imported? For example, core antibody raw materials a: some raw materials are not produced by themselves but purchased. Q5: I see that our products are retailed on the official website. Is there any other channel in the United States? In addition, is it possible for other OEM manufacturers in China to sell directly to the U.S. market? A: the company’s retail channels in the United States are mainly offline channels such as the company’s official website, Amazon e-commerce platform and supermarkets. Whether other Chinese manufacturers can enter the U.S. market mainly depends on the authorization of FDA and EUA. Q6: when did the company start the development of antigen reagent and what was the main difficulty? The company used to be mainly engaged in medical devices. How did it enter this product? A: the company’s main products are sphygmomanometers, but there are also IVD products such as blood glucose meters and blood glucose test papers. The company has a certain accumulation of relevant technologies. The product competition difference of IVD industry is mainly the difference of product quality, sensitivity and specificity. Question 7: at present, the attitude of governments around the world towards the method of family self-test is not consistent. For example, the United States and Europe are more acceptable, and China or other countries may not accept the method of family self-test as a very important testing method, A: first of all, the demand for family self-test is related to the epidemic situation. If the epidemic situation is well controlled and there is no risk of infection and exposure, the demand may be reduced. It is relatively convenient to use the home self-test kit than the nucleic acid test point, and the possibility of using the product in China or / and other countries in the future is not ruled out. However, the sensitivity of the antigen detection kit is lower than that of nucleic acid detection, which still needs to be subject to the detection methods currently approved by Chinese and foreign governments. Q8: if the sensitivity of the kit is not high, there are some missing detection rates, so it is difficult for the Chinese market to accept this method, and we also pay attention to the suggestions of the company and Tianjin municipal government recently. We want to consult the relevant situation. A: the sensitivity of the home self-test kit is lower than that of nucleic acid detection, This product can be used as a self screening tool. The suggestions of the company and Tianjin municipal government are also aimed at families without symptoms in the sealed area. The main consideration is to relatively reduce the possibility of exposure and transmission in the process of nucleic acid detection and the systematic pressure of nucleic acid detection for all staff. Q9: I’d like to ask how much the company currently participates in government procurement and retail channels in the United States, and whether the production capacity can meet the coverage of the two channels at the same time. A: the company has not made statistics yet. The situation of kit products is related to the development of the epidemic. You can see from the public information that the company will comprehensively consider various factors such as market conditions, orders and supply chain, and adjust the production and supply arrangements in real time. Q10: I’d like to ask about the expansion of the company’s upstream and OEM partners. A: at present, the company and its partners
